Marianne Søgaard , Chairwoman of the Board

Mrs. Søgaard served for 22 years at the Kammeradvokaten/Law Firm Poul Schmith as a corporate lawyer, partner and board member. After making partner in January of 2000, Mrs. Søgaard primarily worked with technology and processes to acquire technology solutions at the firm and ultimately served on the firm’s board of directors beginning in 2014. After leaving the firm in 2017, Mrs. Søgaard served on various boards including How to Robot, a platform company supporting the acquisition of physical robots for customers and suppliers and Altapay, a payment solution company. From 2018 to 2020, Mrs. Søgaard joined Evaxion Biotech and served as an executive, corporate lawyer and legal advisor to the company.

Steven Projan, Board member

Steven is the former Sr V.P. R&D and Head of Infectious Disease & Vaccines at MedImmune, retired April 2018. Prior to working at MedImmune, Steve served as V.P., Global and Head of Infectious Disease at Novartis and V.P. and Head of Biological Technologies at Wyeth. Steven is an expert in infectious diseases, having worked many years with both basic and applied research, successfully led four programs resulting in the approval of novel anti-infective drugs with other in various stages of development, and produced more than 110 peer-reviewed publications.

Roberto Prego Pineda, Board member

Roberto was one of the first external investors in Evaxion. Roberto has over 20 years of pharmaceutical experience. He has been country GM and also occupied the position of Regional Leader of the Latin American Region for Teva from 2013 until 2015. He currently manages Viax Dental Technologies, an R&D venture in the Dental field. He has a B.S. of Economics from Universidad Católica Andrés Bello in Caracas, Venezuela and an MBA from Fuqua School of Business at Duke University.

Jo Ann Suzich, Board member

Since April 2020, Dr. Suzich has been Head of Research at Immunocore LLC. From January 2019 until July 2019, she was Microbial Sciences Therapeutic Area Head for Astra Zeneca, from January 2018 until 2019. She was at MedImmune from January 2007 until January 2017 as VP Infectious Disease & Vaccines Research, from January 2017 until January 2018 as VP Microbial Sciences Research and from January 2018 until January 2019 as IMED Head of Infectious Disease & Vaccines. Jo Ann received a PhD in biochemistry from Purdue University.

Helen M. Boudreau, Board member

Helen has 30 years of experience across biotech, pharma, consulting, and banking. Most recently, from June 2018 to June 2019, she served as Chief Operating Officer of the Bill & Melinda Gates Medical Research Institute, a non-profit biotech. Previously, she served as Chief Financial Officer from July 2017 to June 2018 and director and Audit Committee Chair from February 2016 to July 2017 for Proteostasis Therapeutics, Inc. From October 2014 to June 2017, she served as Chief Financial Officer for FORMA Therapeutics, Inc. From September 2008 to September 2014, Helen served in senior finance roles at Novartis, including CFO Novartis Corporation US and CFO Global Oncology. From April 1999 to September 2008, she served in roles of increasing scope and responsibility in strategy and finance at Pfizer, including Vice President Finance Customer Business Unit and Commercial Operations and Vice President Finance, Pfizer Global Research and Development. Helen worked earlier in her career at PepsiCo/YUM! Brands, McKinsey & Company and Bank of America. Since June 2020, she has been a member of the board of Premier, Inc., a healthcare improvement company. She also serves on the boards of Shattuck Labs, Field Trip Health, and Rallybio. Helen earned her B.A. in Economics from the University of Maryland, where she graduated summa cum laude, and her M.B.A. from the Darden Graduate School of Business at the University of Virginia.